Hemostasis or haemostasis is a complex process which causes the bleeding process to stop. Most times this includes the changing of blood from a fluid to a solid state. Intact blood vessels are central to moderating blood's tendency to clot.
HORIBA UK Ltd, Medical announces that a study has shown that UK National External Quality Assessment Scheme for Blood Coagulation external quality assessment lyophilized plasma samples can be tested on its Yumizen G200 hemostasis instrument.
African-Americans are at higher risk for cancer-associated venous thromboembolism (VTE) as compared with patients from other races.
Many patients today are entering the operating room with multiple factors that can cause disruptive bleeding during surgery, which can be challenging to manage and potentially dangerous.
The International Society on Thrombosis and Haemostasis is pleased to announce the official launch of Gene Therapy in Hemophilia: An ISTH Education Initiative.
A collaboration between researchers from Brazil and the United States may open new avenues for the treatment of thrombosis, the leading cause of death among cancer patients.
HORIBA UK Ltd, Medical announces the launch of a D-Dimer parameter for its Yumizen G hemostasis range of instruments.
PENTAX Medical announces the addition of new dedicated electrosurgical and argon plasma coagulation platforms – the ENDO ARC and ENDO PLUS – to its therapeutic accessories range.
A drug that reverses the blood thinning effects of factor Xa inhibitors effectively stopped acute life-threatening bleeding in patients taking a factor Xa inhibitor blood thinner drug, according to late breaking science presented at the American Stroke Association's International Stroke Conference 2019, a world premier meeting for researchers and clinicians dedicated to the science and treatment of cerebrovascular disease.
A new nationally agreed standard of care released today (Thursday) aims to reduce the tens of thousands of Australian lives put at risk each year by largely preventable blood clots, which kill four times more people than road accidents.
The antithrombin drug rivaroxaban does not reduce the risk of a composite endpoint of survival, myocardial infarction and stroke after an episode of worsening heart failure in patients with heart failure, sinus rhythm, and coronary artery disease, according to late breaking results from the COMMANDER HF trial presented today in a Hot Line Session at ESC Congress 2018 and with simultaneous publication in NEJM.
In collaboration with international partners, a study group from the Medical University of Vienna has developed a new model for predicting cancer-associated venous thrombosis/pulmonary embolism.
Exciting data from the 26th European Society of Thoracic Surgeons meeting shows an association between innovation, and improved patient outcomes and lowered hospital costs
HORIBA UK Ltd, Medical announces a significant development of its in vitro diagnostics product offering with the launch of its new Yumizen G range of instruments and reagents.
Bleeding complications dropped by nearly half when surgeons used a powered stapler as opposed to a manual device in what researchers say is the first real-world assessment of the two technologies in video-assisted thoracoscopic surgery for lung cancer.
A penetrating injury from shrapnel is a serious obstacle in overcoming battlefield wounds that can ultimately lead to death.Given the high mortality rates due to hemorrhaging, there is an unmet need to quickly self-administer materials that prevent fatality due to excessive blood loss.
Scientists from ITMO University have found a way to effectively stop internal bleeding by magnetically-driven nanoparticles containing thrombin.
A new study suggests that parmodulins may provide anti-inflammatory and anti-thrombotic protection to endothelial cells, without interfering with clotting.
A 'cure' for hemophilia is one step closer, following results of a groundbreaking gene therapy trial led by the NHS in London.
In three studies being presented today during the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, researchers report remarkable benefits from new, more easily administered therapies for bleeding and clotting disorders.
In a Research and Practice in Thrombosis and Haemostasis study that surveyed the general public in 10 countries, only 48% of people were aware of atrial fibrillation (AF), which is lower than the awareness of other common diseases.